{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:12:30Z","timestamp":1791389550623,"version":"4.3.3"},"reference-count":37,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Alopecia areata (AA) and atopic dermatitis (AD) are complex immune-mediated conditions that frequently coexist in pediatric patients, complicating treatment approaches. Upadacitinib, a selective JAK1 inhibitor, modulates both Th1 and Th2 pathways and is approved for AD in adolescents and adults. This study presents a case series of three adolescent patients with refractory AA and AD treated with upadacitinib 15 mg\/day for 12 months, alongside a comprehensive literature review. All patients demonstrated rapid remission of AD symptoms within the first month and progressive hair regrowth, with SALT scores significantly improving at six and twelve months. No severe adverse events were reported. Notably, one patient achieved complete regrowth despite the presence of ophiasis, a pattern typically associated with poor prognosis. Our literature review identified only four previous pediatric cases successfully treated with upadacitinib, highlighting the novelty of our findings. These cases, together with our experience, suggest that upadacitinib offers a safe and effective therapeutic option for pediatric patients with concomitant AA and AD, including those who failed conventional or biologic therapies such as dupilumab. Larger, controlled studies are needed to confirm long-term efficacy and safety. Our results also support the potential role of upadacitinib in managing multiple Th1\/Th2-mediated comorbidities in pediatric populations.<\/jats:p>","DOI":"10.3390\/jcm14113881","type":"journal-article","created":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T10:21:49Z","timestamp":1748859709000},"page":"3881","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Efficacy of Upadacitinib in Treating Alopecia Areata, Atopic Dermatitis, and Th1 Comorbidities in Pediatric Patients: A Comprehensive Case Series and Literature Review"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-1773-3370","authenticated-orcid":false,"given":"Chiara","family":"Battilotti","sequence":"first","affiliation":[{"name":"Dermatologic Clinic, Sapienza University of Rome, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Azzella","sequence":"additional","affiliation":[{"name":"Dermatologic Clinic, Sapienza University of Rome, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annunziata","family":"Dattola","sequence":"additional","affiliation":[{"name":"Dermatologic Clinic, Sapienza University of Rome, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Rossi","sequence":"additional","affiliation":[{"name":"Dermatologic Clinic, Sapienza University of Rome, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Svara","sequence":"additional","affiliation":[{"name":"Dermatologic Clinic, Sapienza University of Rome, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Chello","sequence":"additional","affiliation":[{"name":"Dermatologic Clinic, Sapienza University of Rome, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7948-8536","authenticated-orcid":false,"given":"Ester","family":"Del Duca","sequence":"additional","affiliation":[{"name":"Dermatologic Clinic, Sapienza University of Rome, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Paolino","sequence":"additional","affiliation":[{"name":"Unit of Dermatology, IRCCS Ospedale San Raffaele, 20132 Milan, Italy"},{"name":"Unit of Clinical Dermatology, Universit\u00e0 Vita-Salute San Raffaele, 20132 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3828-0883","authenticated-orcid":false,"given":"Steven P.","family":"Nistic\u00f2","sequence":"additional","affiliation":[{"name":"Dermatologic Clinic, Sapienza University of Rome, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Pellacani","sequence":"additional","affiliation":[{"name":"Dermatologic Clinic, Sapienza University of Rome, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7855-6621","authenticated-orcid":false,"given":"Teresa","family":"Grieco","sequence":"additional","affiliation":[{"name":"Dermatologic Clinic, Sapienza University of Rome, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,5,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.annder.2022.03.006","article-title":"Alopecia areata: Recent advances and emerging therapies","volume":"149","author":"Seneschal","year":"2022","journal-title":"Ann. Dermatol. V\u00e9n\u00e9r\u00e9ologie"},{"key":"ref_2","unstructured":"Lepe, K., Syed, H.A., and Zito, P.M. (2025). Alopecia Areata. StatPearls, StatPearls Publishing."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jdermsci.2023.09.008","article-title":"Alopecia areata: What\u2019s new in the epidemiology, comorbidities, and pathogenesis?","volume":"112","author":"Dainichi","year":"2023","journal-title":"J. Dermatol. Sci."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Sroka-Tomaszewska, J., and Trzeciak, M. (2021). Molecular Mechanisms of Atopic Dermatitis Pathogenesis. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22084130"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.jid.2023.10.019","article-title":"Genetic and Immunological Pathogenesis of Atopic Dermatitis","volume":"144","author":"Schuler","year":"2024","journal-title":"J. Investig. Dermatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1016\/j.jaci.2017.01.011","article-title":"The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies","volume":"139","author":"Brunner","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.abd.2024.06.001","article-title":"Update on the pathogenesis of atopic dermatitis","volume":"99","author":"Criado","year":"2024","journal-title":"An. Bras. Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Zhou, W., Cai, J., Li, Z., and Lin, Y. (2023). Association of atopic dermatitis with autoimmune diseases: A bidirectional and multivariable two-sample mendelian randomization study. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1132719"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1097\/01.ASW.0000547414.38888.8d","article-title":"Diagnosis and Management of Atopic Dermatitis: A Review","volume":"31","author":"Maliyar","year":"2018","journal-title":"Adv. Ski. Wound Care"},{"key":"ref_10","first-page":"609","article-title":"Italian Guidelines in diagnosis and treatment of alopecia areata","volume":"154","author":"Rossi","year":"2019","journal-title":"Ital. J. Dermatol. Venereol."},{"key":"ref_11","unstructured":"Sanofi (2024, July 25). Press Release: FDA Approves Dupixent\u00ae (Dupilumab) as First Biologic Medicine for Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis. Available online: https:\/\/www.sanofi.com\/en\/media-room\/press-releases\/2022\/2022-06-07-20-45-00-2458243."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"5","DOI":"10.14712\/23362936.2023.1","article-title":"Janus Kinase Inhibitors in the Treatment of Alopecia Areata","volume":"124","author":"Stefanis","year":"2023","journal-title":"Prague Med. Rep."},{"key":"ref_13","first-page":"e223","article-title":"Improvement of alopecia areata with Dupilumab in a patient with severe atopic dermatitis and review the literature","volume":"61","year":"2020","journal-title":"Australas. J. Dermatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"799","DOI":"10.25259\/IJDVL_1093_2022","article-title":"Janus kinase inhibitors for alopecia areata: A narrative review","volume":"89","author":"Haughton","year":"2023","journal-title":"Indian J. Dermatol. Venereol. Leprol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Mohamed, M.-E.F., Bhatnagar, S., Parmentier, J.M., Nakasato, P., and Wung, P. (2024). Upadacitinib: Mechanism of action, clinical, and translational science. Clin. Transl. Sci., 17.","DOI":"10.1111\/cts.13688"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Grieco, T., Caviglia, M., Cusano, G., Sernicola, A., Chello, C., Del Duca, E., Cantisani, C., Taliano, A., Sini, N., and Ianiro, G. (2023). Atopic Dermatitis and Ulcerative Colitis Successfully Treated with Upadacitinib. Medicina, 59.","DOI":"10.3390\/medicina59030542"},{"key":"ref_17","unstructured":"Rinvoq (2022, December 14). Summary of Product Characteristics. AbbVie Deutschland GmbH. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/rinvoq-epar-product-information_en.pdf."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Bourkas, A.N., and Sibbald, C. (2022). Upadacitinib for the treatment of alopecia areata and severe atopic dermatitis in a paediatric patient: A case report. SAGE Open Med. Case Rep., 10.","DOI":"10.1177\/2050313X221138452"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s13555-023-00889-0","article-title":"Alopecia Universalis in an Adolescent Successfully Treated with Upadacitinib\u2014A Case Report and Review of the Literature on the Use of JAK Inhibitors in Pediatric Alopecia Areata","volume":"13","author":"Reich","year":"2023","journal-title":"Dermatol. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"adv5578","DOI":"10.2340\/actadv.v103.5578","article-title":"Upadacitinib for Successful Treatment of Alopecia Universalis in a Child: A Case Report and Literature Review","volume":"103","author":"Yu","year":"2023","journal-title":"Acta Derm. Venereol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/pde.15504","article-title":"Improvement of severe alopecia areata in an adolescent patient on upadacitinib","volume":"41","author":"Ha","year":"2024","journal-title":"Pediatr. Dermatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s12016-021-08883-0","article-title":"Alopecia Areata: An Update on Etiopathogenesis, Diagnosis, and Management","volume":"61","author":"Zhou","year":"2021","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/pde.15803","article-title":"Epidemiology of Pediatric Alopecia Areata","volume":"1","author":"Adhanom","year":"2025","journal-title":"Pediatr. Dermatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.abd.2023.03.001","article-title":"JAK-STAT pathway inhibitors in dermatology","volume":"98","author":"Miot","year":"2023","journal-title":"An. Bras. Dermatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","article-title":"The JAK\/STAT signaling pathway: From bench to clinic","volume":"6","author":"Hu","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_26","first-page":"1","article-title":"The Evolving Story of JAK Inhibitors for Treating Alopecia Areata: A Review of Current Progress and Future Directions","volume":"28","author":"Donovan","year":"2023","journal-title":"Ski. Ther. Lett."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1007\/s00403-024-03182-y","article-title":"Ritlecitinib, a JAK3\/TEC family kinase inhibitor, stabilizes active lesions and repigments stable lesions in vitiligo","volume":"316","author":"Yamaguchi","year":"2024","journal-title":"Arch. Dermatol. Res."},{"key":"ref_28","unstructured":"Padda, I.S., Bhatt, R., Patel, P., and Parmar, M. (2025). StatPearls, StatPearls Publishing."},{"key":"ref_29","first-page":"69","article-title":"Mechanisms of Development and Characteristics the Pathology of the Gastrointestinal Tract in Chronic Pancreatitis","volume":"11","author":"Byikova","year":"2016","journal-title":"Eksp. Klin. Gastroenterol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1001\/jamadermatol.2023.0391","article-title":"Efficacy and Safety of Upadacitinib Treatment in Adolescents With Moderate-to-Severe Atopic Dermatitis: Analysis of the Measure Up 1, Measure Up 2, and AD Up Randomized Clinical Trials","volume":"159","author":"Paller","year":"2023","journal-title":"JAMA Dermatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s00403-025-03890-z","article-title":"Off-label use of JAK1 inhibitor upadacitinib in dermatology","volume":"317","author":"Zhang","year":"2025","journal-title":"Arch. Dermatol. Res."},{"key":"ref_32","first-page":"751","article-title":"Alopecia areata: Part 1: Pathogenesis, diagnosis, and prognosis","volume":"61","author":"Spano","year":"2015","journal-title":"Can. Fam. Physician"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.jaad.2003.09.032","article-title":"Alopecia areata investigational assessment guidelines\u2014Part II","volume":"51","author":"Olsen","year":"2004","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1056\/NEJMoa2110343","article-title":"For the BRAVE-AA Investigators. Two Phase 3 Trials of Baricitinib for Alopecia Areata","volume":"386","author":"King","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1034\/j.1600-0625.2001.100102.x","article-title":"The eczema area and severity index (EASI): Assessment of reliability in atopic dermatitis. EASI Evaluator Group","volume":"10","author":"Hanifin","year":"2001","journal-title":"Exp. Dermatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/bjd.17744","article-title":"Peak Pruritus Numerical Rating Scale: Psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis","volume":"181","author":"Yosipovitch","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"ref_37","first-page":"942","article-title":"The Children\u2019s Dermatology Life Quality Index (CDLQI): Initial validation and practical use","volume":"132","author":"Finlay","year":"1995","journal-title":"Br. J. Dermatol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/11\/3881\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:44:29Z","timestamp":1760031869000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/11\/3881"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,30]]},"references-count":37,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["jcm14113881"],"URL":"https:\/\/doi.org\/10.3390\/jcm14113881","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,30]]}}}